Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy

NCT00008866 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: Tetanus Toxoid Vaccine
DRUG: Hydroxyurea
DRUG: Didanosine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)